BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis

Area of Science:

• Cancer Biology
• Molecular Oncology
• Drug Development

Background:

• Argininosuccinate synthetase 1 (ASS1) silencing in cancers creates a dependency on extracellular arginine.
• Arginine deprivation therapies like ADI-PEG20 show limited efficacy due to apoptosis inhibition.

Purpose of the Study:

• To investigate the effects of ADI-PEG20 on cell-cycle regulation, apoptosis, and BCL-XL-mediated survival in ASS1-deficient cancer cells.
• To elucidate the mechanism of cell death protection and identify strategies to enhance therapeutic outcomes.

Main Methods:

• Assessed caspase and PARP cleavage, CDK2 activity, MCL1 expression, and BCL-XL/BAX/BAK interactions.
• Determined in vitro synergy and modeled in vivo efficacy of ADI-PEG20, alone and in combination with BCL-XL inhibitors.

Main Results:

• ADI-PEG20 reduced CDK2 activity and inhibited cell-cycle progression but did not induce significant cell death.
• BCL-XL binding to BAX and BAK prevented apoptosis initiation; BCL-XL inhibition enabled apoptosis.
• Combination therapy demonstrated in vitro synergy and in vivo efficacy.

Conclusions:

• BCL-XL is a key factor limiting arginine starvation therapy efficacy.
• Combining BCL-XL inhibitors with arginine deprivation strategies can overcome resistance.
• Provides a preclinical rationale for clinical trials of this combination in ASS1-deficient cancers.